Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA21025BX" target="_blank" >RIV/61988987:17110/19:A21025BX - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216224:14110/19:00111746 RIV/61989592:15110/19:73598732 RIV/00098892:_____/19:N0000092

  • Výsledek na webu

    <a href="http://website60s.com/upload/files/cytokine-vol-122-4.pdf" target="_blank" >http://website60s.com/upload/files/cytokine-vol-122-4.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.cyto.2017.03.016" target="_blank" >10.1016/j.cyto.2017.03.016</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls

  • Popis výsledku v původním jazyce

    Objectives: Little is known about the role of adipokines in the pathogenesis of coronary artery disease in young patients. The aims of this study were to compare serum levels of adipokines and expression of adipokines in peripheral blood leukocytes in patients with premature coronary artery disease (CAD), metabolic syndrome and healthy individuals.Design and methods: Sixty-five patients with premature CAD (men 18–45 years old and women 18–55 years old)formed the study group. The control groups were 75 patients with metabolic syndrome and 50 healthy individuals. For each group, RNA expression in peripheral blood leukocytes was determined for 24 different adipokines and 11 adipokines were examined in serum. Results: In individuals with CAD, serum visfatin levels were significantly higher than in metabolic syndrome and healthy controls (2.3 vs. 1.6 vs. 0.7 µg/L, P < 0.001) while both omentin-1 (92.9 vs. 587.0 vs. 552.3 µg/L,P < 0.001) and ZAG2 (45.5 vs. 72.5 vs. 77.1 mg/L, P < 0.001) levels were lower. The receiver operating curve (ROC) analysis for testing the validity of these adipokines in the diagnosis of CAD compared to control groups provided the following areas under the curve (AUC): omentin-1 AUC 0.97 (cut-off ≤222 µg/L), ZAG2 AUC 0.89 (cut-off ≤51.7 mg/L) and visfatin AUC 0.74 (cut-off ≥1.0 µg/L) (P < 0.001 in all cases). Visfatin and omentin1 serum levels did not differ between the acute phase of myocardial infarction and the chronic phase of CAD. In patients with CAD, we found no significant relation between mRNA expression and adipokine concentration.Conclusion: Serum omentin-1, visfatin and ZAG2 could serve as biomarkers of premature CAD in young apparently healthy people.

  • Název v anglickém jazyce

    Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls

  • Popis výsledku anglicky

    Objectives: Little is known about the role of adipokines in the pathogenesis of coronary artery disease in young patients. The aims of this study were to compare serum levels of adipokines and expression of adipokines in peripheral blood leukocytes in patients with premature coronary artery disease (CAD), metabolic syndrome and healthy individuals.Design and methods: Sixty-five patients with premature CAD (men 18–45 years old and women 18–55 years old)formed the study group. The control groups were 75 patients with metabolic syndrome and 50 healthy individuals. For each group, RNA expression in peripheral blood leukocytes was determined for 24 different adipokines and 11 adipokines were examined in serum. Results: In individuals with CAD, serum visfatin levels were significantly higher than in metabolic syndrome and healthy controls (2.3 vs. 1.6 vs. 0.7 µg/L, P < 0.001) while both omentin-1 (92.9 vs. 587.0 vs. 552.3 µg/L,P < 0.001) and ZAG2 (45.5 vs. 72.5 vs. 77.1 mg/L, P < 0.001) levels were lower. The receiver operating curve (ROC) analysis for testing the validity of these adipokines in the diagnosis of CAD compared to control groups provided the following areas under the curve (AUC): omentin-1 AUC 0.97 (cut-off ≤222 µg/L), ZAG2 AUC 0.89 (cut-off ≤51.7 mg/L) and visfatin AUC 0.74 (cut-off ≥1.0 µg/L) (P < 0.001 in all cases). Visfatin and omentin1 serum levels did not differ between the acute phase of myocardial infarction and the chronic phase of CAD. In patients with CAD, we found no significant relation between mRNA expression and adipokine concentration.Conclusion: Serum omentin-1, visfatin and ZAG2 could serve as biomarkers of premature CAD in young apparently healthy people.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    10608 - Biochemistry and molecular biology

Návaznosti výsledku

  • Projekt

  • Návaznosti

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    CYTOKINE

  • ISSN

    1043-4666

  • e-ISSN

    1096-0023

  • Svazek periodika

    122

  • Číslo periodika v rámci svazku

    SI

  • Stát vydavatele periodika

    GB - Spojené království Velké Británie a Severního Irska

  • Počet stran výsledku

    7

  • Strana od-do

  • Kód UT WoS článku

    000488662600003

  • EID výsledku v databázi Scopus